387-19-9 Usage
General Description
N-(2-nitro-3-(trifluoroMethyl)phenyl)acetaMide is a chemical compound that is commonly used in pharmaceutical research and organic synthesis. It is an amide derivative of 2-nitro-3-(trifluoroMethyl)aniline and is known for its ability to act as an effective intermediate in the production of various medications and organic compounds. N-(2-nitro-3-(trifluoroMethyl)phenyl)acetaMide is characterized by its nitro and trifluoromethyl functional groups, which make it useful for a range of chemical reactions and transformations. Additionally, it has been studied for its potential biological activities and medicinal properties, making it a valuable component in the development of new drugs and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 387-19-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,8 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 387-19:
(5*3)+(4*8)+(3*7)+(2*1)+(1*9)=79
79 % 10 = 9
So 387-19-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H7F3N2O3/c1-5(15)13-7-4-2-3-6(9(10,11)12)8(7)14(16)17/h2-4H,1H3,(H,13,15)
387-19-9Relevant articles and documents
SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
-
Paragraph 00497, (2021/04/01)
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
Page/Page column 101, (2010/11/03)
The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.
